A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer

17115 Background: The combination of gemcitabine and cisplatin is among the most active regimens for the treatment of NSCLC. However, the optimal dose and schedule for administration of the two dru...